EAM
CLB icon

Eagle Asset Management’s Core Laboratories CLB Stock Holding History

Eagle Asset Management’s Portfolio CLB Stock Details CLB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$3.96M Buy
+190,546
New +$3.83M 0.02% 411
2020
Q3 		– Sell
-134,578
Closed -$2.61M – 577
2020
Q2 		$2.61M Buy
134,578
+1,394
+1% +$25K 0.01% 424
2020
Q1 		$1.38M Buy
133,184
+19,232
+17% +$538K 0.01% 495
2019
Q4 		$4.29M Buy
113,952
+35,643
+46% +$1.6M 0.02% 429
2019
Q3 		$3.65M Buy
78,309
+4,019
+5% +$187K 0.02% 454
2019
Q2 		$3.88M Sell
74,290
-1,527
-2% -$89.6K 0.02% 434
2019
Q1 		$5.23M Buy
75,817
+1,905
+3% +$128K 0.03% 405
2018
Q4 		$4.41M Sell
73,912
-1,607
-2% -$139K 0.03% 405
2018
Q3 		$8.75M Buy
75,519
+1,395
+2% +$157K 0.04% 357
2018
Q2 		$9.36M Sell
74,124
-21,390
-22% -$2.6M 0.05% 331
2018
Q1 		$10.3M Buy
95,514
+11,214
+13% +$1.24M 0.06% 311
2017
Q4 		$9.29M Buy
84,300
+28,063
+50% +$2.8M 0.05% 332
2017
Q3 		$5.55M Buy
56,237
+1,136
+2% +$110K 0.03% 421
2017
Q2 		$5.58M Buy
55,101
+169
+0.3% +$18.2K 0.03% 415
2017
Q1 		$6.34M Buy
54,932
+21,417
+64% +$2.49M 0.04% 386
2016
Q4 		$4.02M Buy
33,515
+5,563
+20% +$616K 0.03% 443
2016
Q3 		$3.14M Sell
27,952
-874
-3% -$101K 0.02% 492
2016
Q2 		$3.57M Buy
28,826
+5,271
+22% +$636K 0.02% 460
2016
Q1 		$2.65M Sell
23,555
-1,539
-6% -$160K 0.02% 508
2015
Q4 		$2.73M Sell
25,094
-328
-1% -$37.5K 0.02% 508
2015
Q3 		$2.54M Sell
25,422
-639
-2% -$69.5K 0.02% 518
2015
Q2 		$2.97M Sell
26,061
-1,552
-6% -$188K 0.02% 508
2015
Q1 		$2.88M Buy
27,613
+11,707
+74% +$1.25M 0.02% 491
2014
Q4 		$1.91M Sell
15,906
-10,678
-40% -$1.4M 0.01% 553
2014
Q3 		$3.89M Buy
26,584
+8,298
+45% +$1.28M 0.02% 471
2014
Q2 		$3.05M Sell
18,286
-2,546
-12% -$453K 0.02% 545
2014
Q1 		$4.13M Sell
20,832
-905
-4% -$171K 0.02% 501
2013
Q4 		$4.15M Sell
21,737
-1,054
-5% -$196K 0.02% 464
2013
Q3 		$3.86M Sell
22,791
-6,244
-22% -$969K 0.02% 534
2013
Q2 		$4.4M Buy
+29,035
New +$4.11M 0.03% 476

Other funds holding CLB

AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $5.91B AUM 53.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Eagle Asset Management's CLB Position: Q3 2024 in Review

Eagle Asset Management opened a new position in Core Laboratories (CLB) in Q3 2024: 190,546 shares worth $3.96M. The stake represents 0.02% of the portfolio and ranks #411 among its holdings. This is a return to the name: Eagle Asset Management previously reported a position in CLB as recently as Q2 2020.

Eagle Asset Management first reported a position in CLB in Q2 2013 and has held it in 30 quarters since. The position peaked at $10.3M in Q1 2018. 191 funds tracked by Wall St. Rank hold CLB as of Q3 2024.

  • Eagle Asset Management held 190,546 shares of Core Laboratories worth $3.96M as of Q3 2024.
  • Core Laboratories was a new Eagle Asset Management position in Q3 2024.
  • Core Laboratories made up 0.02% of Eagle Asset Management's portfolio in Q3 2024, its #411 holding.
  • Eagle Asset Management first reported a position in Core Laboratories in Q2 2013 and has held it in 30 quarters since.
  • Eagle Asset Management's Core Laboratories position peaked at $10.3M in Q1 2018.
  • 191 funds tracked by Wall St. Rank held Core Laboratories as of Q3 2024.

Based on Eagle Asset Management's 13F filing for Q3 2024, filed 12 Nov 2024.